174 related articles for article (PubMed ID: 30938822)
1. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
[No Abstract] [Full Text] [Related]
2. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
Dasanu CA
J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
[TBL] [Abstract][Full Text] [Related]
3. Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation.
Komori T; Honda T; Irie H; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e382-e384. PubMed ID: 28295693
[No Abstract] [Full Text] [Related]
4. Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
Komatsu-Fujii T; Ogawa M; Nonoyama S; Fukumoto T; Tanabe H
Eur J Dermatol; 2021 Feb; 31(1):98-99. PubMed ID: 33586655
[No Abstract] [Full Text] [Related]
5. Linear bullous lichen planus associated with nivolumab.
Biolo G; Caroppo F; Salmaso R; Alaibac M
Clin Exp Dermatol; 2019 Jan; 44(1):67-68. PubMed ID: 29920744
[No Abstract] [Full Text] [Related]
6. Nivolumab-induced lichen planus pemphigoides.
Strickley JD; Vence LM; Burton SK; Callen JP
Cutis; 2019 Apr; 103(4):224-226. PubMed ID: 31116807
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Ziemer CM; Miedema J; Smith CJ; Liu Z; Thomas NE; Googe PB
Am J Dermatopathol; 2021 Apr; 43(4):318-320. PubMed ID: 33055536
[No Abstract] [Full Text] [Related]
8. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
[No Abstract] [Full Text] [Related]
9. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
[TBL] [Abstract][Full Text] [Related]
10. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
[No Abstract] [Full Text] [Related]
11. Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy.
Matsumoto Y; Kadono T; Matsuoka M; Kawakami T; Furuya N; Doi M; Hoshikawa M; Soma Y
J Dermatol; 2018 Feb; 45(2):e33-e34. PubMed ID: 28984022
[No Abstract] [Full Text] [Related]
12. Nivolumab-induced lichen planus.
Yilmaz M; Mese SG; Celik U
J Oncol Pharm Pract; 2020 Apr; 26(3):758-760. PubMed ID: 31382865
[TBL] [Abstract][Full Text] [Related]
13. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
[TBL] [Abstract][Full Text] [Related]
14. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
Sato Y; Fujimura T; Mizuashi M; Aiba S
J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
[No Abstract] [Full Text] [Related]
15. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
[No Abstract] [Full Text] [Related]
16. Umbilical lichen planus induced by nivolumab.
Martos-Cabrera L; Lladó I; Fernández-Rico P; Butrón-Bris B; Rodríguez-Jiménez P
An Bras Dermatol; 2023; 98(5):712-714. PubMed ID: 37164791
[No Abstract] [Full Text] [Related]
17. Nivolumab-induced Stevens-Johnson syndrome: Not only due to PD-1 inhibition.
Rodríguez-Otero N; Chamorro-Pérez J; Fernández-Lozano C; Elías-Sáenz I; Berná-Rico E; de Nicolás-Ruanes B; Meléndez-Gispert MR; Moreno-García Del Real C; Martínez-Botas J; Cortés-Salgado A; Solano-Solares E
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2936-2938.e1. PubMed ID: 37308058
[No Abstract] [Full Text] [Related]
18. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.
Reschke R; Mockenhaupt M; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2019 Sep; 17(9):942-948. PubMed ID: 31210413
[No Abstract] [Full Text] [Related]
19. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis.
Kubo K; Kato M; Mabe K
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):A35-A36. PubMed ID: 28351793
[No Abstract] [Full Text] [Related]
20. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
Bednarek R; Marks K; Lin G
Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
[No Abstract] [Full Text] [Related]
[Next] [New Search]
